Search research articles
Contact Us
Filters
Showing results (371-380 of 703) with videos related to
Page
of 71
Sort By:
The Lancet. Oncology
|
February 15, 2021
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study
Mahrukh M Syeda, Jennifer M Wiggins, Broderick C Corless, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 16, 2021
G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma
Gregory M Kelly, Fares Al-Ejeh, Robert McCuaig, et al.
The Lancet. Oncology
|
February 4, 2014
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials
Keith T Flaherty, Michael Hennig, Sandra J Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 28, 2014
BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact
Helen Rizos, Alexander M Menzies, Gulietta M Pupo, et al.
Nature Cancer
|
August 29, 2024
A targetable type III immune response with increase of IL-17A expressing CD4<sup>+</sup> T cells is associated with immunotherapy-induced toxicity in melanoma
Florentia Dimitriou, Phil F Cheng, Annalisa Saltari, et al.
British Journal of Cancer
|
April 29, 2016
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
S Bowyer, P Prithviraj, P Lorigan, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 26, 2023
Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation
Alison M Weppler, Laetitia Da Meda, Ines Pires da Silva, et al.
Nature Communications
|
April 8, 2024
Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma
Xinyu Bai, Grace H Attrill, Tuba N Gide, et al.
Molecular Cancer Research : MCR
|
March 6, 2019
Somatic Hypermutation of the <i>YAP</i> Oncogene in a Human Cutaneous Melanoma
Xiaomeng Zhang, Jian Zhong Tang, Ismael A Vergara, et al.
The Lancet. Oncology
|
February 3, 2020
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF<sup>V600</sup>-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
Reinhard Dummer, Jan C Brase, James Garrett, et al.
Page
of 71
Search research articles
Search
Showing results (371-380 of 703) with videos related to
Sort By:
Page
of 71
The Lancet. Oncology
|
February 15, 2021
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study
Mahrukh M Syeda, Jennifer M Wiggins, Broderick C Corless, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 16, 2021
G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma
Gregory M Kelly, Fares Al-Ejeh, Robert McCuaig, et al.
The Lancet. Oncology
|
February 4, 2014
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials
Keith T Flaherty, Michael Hennig, Sandra J Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 28, 2014
BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact
Helen Rizos, Alexander M Menzies, Gulietta M Pupo, et al.
Nature Cancer
|
August 29, 2024
A targetable type III immune response with increase of IL-17A expressing CD4<sup>+</sup> T cells is associated with immunotherapy-induced toxicity in melanoma
Florentia Dimitriou, Phil F Cheng, Annalisa Saltari, et al.
British Journal of Cancer
|
April 29, 2016
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
S Bowyer, P Prithviraj, P Lorigan, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 26, 2023
Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation
Alison M Weppler, Laetitia Da Meda, Ines Pires da Silva, et al.
Nature Communications
|
April 8, 2024
Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma
Xinyu Bai, Grace H Attrill, Tuba N Gide, et al.
Molecular Cancer Research : MCR
|
March 6, 2019
Somatic Hypermutation of the <i>YAP</i> Oncogene in a Human Cutaneous Melanoma
Xiaomeng Zhang, Jian Zhong Tang, Ismael A Vergara, et al.
The Lancet. Oncology
|
February 3, 2020
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF<sup>V600</sup>-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
Reinhard Dummer, Jan C Brase, James Garrett, et al.
Page
of 71